ALEXIS Biochemicals: Polyclonal Antibody to Secretory Leukocyte Proteinase Inhibitor (human)

ALX-210-376

Revised 19-Jun-07

Polyclonal Antibody to Secretory Leukocyte Proteinase Inhibitor (human)
SYNONYMS	anti-SLPI (human) PAb anti-Antileukoproteinase 1 (human) PAb anti-ALP (human) PAb
PRODUCT LINE	Immunology
PRODUCT CATEGORY	Antimicrobial Peptides & Proteins / Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-210-376-C100		100 µg	220.00 USD

Product Specification

SPECIES CROSSREACTIVITY:	Human
SOURCE/HOST:	From rabbit.
CONCENTRATION:	0.1mg/ml.
PURITY DETAIL:	Protein G-affinity purified. 0.2µm-membrane filtered.
FORMULATION:	Liquid. In PBS containing 15mM sodium azide.
IMMUNOGEN:	Synthetic peptide corresponding to aa75-89 (P⁷⁵VDTPNPTRRKPGKC⁸⁹) of human SLPI (secretory leukocyte proteinase inhibitor).
SPECIFICITY:	Recognizes human SLPI.
APPLICATION:	ELISA Immunohistochemistry (frozen sections (1:100-1:1'000), paraffin sections (1:100-1:1'000)) Western Blot
SHIPPING:	SHIPPED ON BLUE ICE
LONG TERM STORAGE:	+4°C
HANDLING:	Do not freeze.

Product Specific Literature References

Protease-protease inhibitor balance in the gastric mucosa. Influence of Helicobacter pylori infection: M. Nilius, et al.; Adv. Exp. Med. Biol. 477, 445 (2000) Abstract

General Information

Secretory leukoprotease inhibitor (SLPI) is a low molecular weight serine proteinase inhibitor found on various mucosal surfaces and has been ascribed an important role in maintaining the protease-anti-protease balance of the airways. SLPI is produced by various epithelia and also possibly by neutrophils, mast cells and macrophages. Various studies have demonstrated the importance of serine proteinase inhibitors in regulating the activity of serine proteinases that are released by leukocytes during inflammation. Lipopolysaccharides (LPS) are able to up-regulate SPLI production in macrophages and addition of recombinant SLPI to human monocytes can down-regulate pro-inflammatory mediators such as tumor necrosis factor (TNF), presumably to limit self-damaging excessive inflammation. SLPI may also have a broad spectrum antibiotic activity that includes antiretroviral (e.g. HIV), bactericidal and antifungal activity.
SLPI is a cationic, non-glycosylated 11.7kDa protein (107aa)comprising two domains (trypsin inhibitory domain, aa26-83 and elastase inhibitory domain, aa84-132). Its major target is thought to be the human neutrophil elastase, but SLPI also inhibits the neutrophil proteinase cathepsin G, pancreatic trypsin and chymotrypsin, as well as mast cell chymase and tryptase.

General Literature References

Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option?: J.F. Tomee, et al.; Thorax 53, 114 (1998), (Review) Abstract
The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease: J.M. Sallenave; Respir. Res. 1, 87 (2000), (Review) Abstract; Full Text
Antimicrobial activity of antiproteinases: J.M. Sallenave; Biochem. Soc. Trans. 30, 111 (2002), (Review) Abstract; Full Text
Novel roles of protease inhibitors in infection and inflammation: P.S. Hiemstra; Biochem. Soc. Trans. 30, 116 (2002), (Review) Abstract; Full Text

Further Categories Containing This Product:

Inflammation Other Products • Proteases Other Products • Polyclonal Antibodies

another CS2 website

Online Product Ordering

Clipboard [0]

Your items will be kept only for the duration of your visit.